ELOX (Eloxx Pharmaceuticals) Total Liabilities: $17.18 Mil (As of Dec. 2025)


ELOX Eloxx Pharmaceuticals Inc ELOX
17 GF Score
Price $12.50
! 2 Warning Signs
View Full Analysis

What is Eloxx Pharmaceuticals Total Liabilities?

Eloxx Pharmaceuticals ELOX -9.94% 17 Total Liabilities is $17.18 Mil as of Dec. 2025. GuruFocus rates ELOX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

Eloxx Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was $17.18 Mil.

Eloxx Pharmaceuticals's quarterly Total Liabilities increased from Dec. 2023 ($24.31 Mil) to Dec. 2024 ($27.31 Mil) but then declined from Dec. 2024 ($27.31 Mil) to Dec. 2025 ($17.18 Mil).

Eloxx Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 ($24.31 Mil) to Dec. 2024 ($27.31 Mil) but then declined from Dec. 2024 ($27.31 Mil) to Dec. 2025 ($17.18 Mil).


Eloxx Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Eloxx Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eloxx Pharmaceuticals Total Liabilities Chart

Eloxx Pharmaceuticals Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.76 31.78 24.31 27.31 17.18

Eloxx Pharmaceuticals Semi-Annual Data
Jun06 Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.76 31.78 24.31 27.31 17.18
ELOX
17GF Score
Eloxx Pharmaceuticals Inc ELOX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eloxx Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Eloxx Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=5.27--11.907
=17.18

Eloxx Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=5.27--11.907
=17.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $17.18 Mil mean?
Eloxx Pharmaceuticals (ELOX) has a Total Liabilities of $17.18 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Eloxx Pharmaceuticals and its competitors.
Is Eloxx Pharmaceuticals' Total Liabilities too high?
Eloxx Pharmaceuticals' current Total Liabilities is $17.18 Mil. Overall, Eloxx Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Eloxx Pharmaceuticals' Total Liabilities compare to ESLA and RNXT?
Eloxx Pharmaceuticals' Total Liabilities of $17.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Eloxx Pharmaceuticals and its competitors. Eloxx Pharmaceuticals's current Total Liabilities is $17.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eloxx Pharmaceuticals stock overvalued right now?
Eloxx Pharmaceuticals (ELOX) has a current Total Liabilities of $17.18 Mil. The current Total Liabilities is $17.18 Mil. Eloxx Pharmaceuticals' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Eloxx Pharmaceuticals (ELOX), the current Total Liabilities is $17.18 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eloxx Pharmaceuticals Business Description

Address 10 Court Street, P.O. Box 274, Arlington, MA, USA, 02476
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
17GF Score

Get the complete analysis for ELOX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.50
Price